US health panel recommends easing restrictions on controversial peptides
A federal health advisory panel narrowly recommended easing restrictions on several injectable peptides, including BPC-157, TB-500, and KPV, which are popular among wellness influencers and celebrities. The panel, whose members include individuals linked to the peptide industry, voted 8-6 to suggest the FDA remove current restrictions barring pharmacies from compounding these substances.

Briefing Summary
AI-generatedA federal health advisory panel narrowly recommended easing restrictions on several injectable peptides, including BPC-157, TB-500, and KPV, which are popular among wellness influencers and celebrities. The panel, whose members include individuals linked to the peptide industry, voted 8-6 to suggest the FDA remove current restrictions barring pharmacies from compounding these substances. This recommendation comes despite warnings from FDA scientists about the lack of evidence for the peptides' safety and effectiveness. The panel's vote is advisory, but it is expected to support Health Secretary Robert F. Kennedy Jr., who has expressed support for peptides. If the FDA accepts the advice, telehealth companies may increase marketing of these peptides for unproven wellness and cosmetic uses.
Article analysis
Model · rule-basedKey claims
5 extractedGovernment scientists warned that the chemicals have not been shown to be safe or effective.
Medical experts describe the marketplace as a 'wild west' of unproven, unregulated drugs that could cause serious harm.
A federal health panel narrowly recommended easing restrictions on several peptides popular with wellness influencers and celebrities.
The panel's vote is not binding but is likely to embolden the health secretary, Robert F Kennedy Jr, who has described himself as a 'big fan' of peptides.
Panel members with backgrounds in academia, rather than peptides, mostly voted against the substances.